NEW YORK, December 5, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Mindray Medical International Limited (NYSE: MR), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Mindray Medical International Limited Research Report
On November 26, 2013, Mindray Medical International Limited (Mindray) announced that it will host its 2013 annual general meeting of record at the Company's Hong Kong office on December 17, 2013 at 11:00 a.m. Beijing/Hong Kong Time (December 16, 2013 at 10:00 p.m. US ET). Mindray reported that the shareholder record date is November 12, 2013. In addition, Mindray informed that its Form 20-F and proxy materials are accessible through the Investor Relations website. The Full Research Report on Mindray Medical International Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
AcelRx Pharmaceuticals, Inc. Research Report
On December 2, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that its Zalviso New Drug Application (NDA) was accepted for filing by the FDA on November 26, 2013. Richard King, President and CEO of AcelRx commented, "We are extremely pleased with the filing of our NDA for Zalviso, representing achievement of another critical milestone for AcelRx. Zalviso, if approved, will provide hospitalized patients with a non-programmable, non-invasive, patient-controlled treatment option for the management of moderate-to-severe acute pain with a rapid onset of pain relief compared to the commonly used, intravenous patient controlled analgesia systems that typically utilize morphine." The Full Research Report on AcelRx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Merrimack Pharmaceuticals, Inc. Research Report
On November 26, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced results of two Phase 2 studies evaluating MM-121 in the treatment of women with ER/PR+, HER2 negative breast cancer. Merrimack reported that the MM-121 is a monoclonal antibody designed to target the ErbB3 (HER3) receptor and to interfere with growth factor-mediated resistance to standard-of-care therapies. According to Merrimack, one study was conducted in metastatic breast cancer (mBC) in combination with exemestane, while the second study was conducted in the neoadjuvant setting in combination with paclitaxel followed by doxorubicin and cyclophosphamide. The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ZELTIQ Aesthetics, Inc. Research Report
On December 2, 2013, ZELTIQ Aesthetics, Inc. (ZELTIQ) announced that the Company is participating at the upcoming J.P. Morgan SMid Cap Conference at The Westin River North in Chicago on December 11, 2013. According to ZELTIQ, Patrick F. Williams, Senior Vice President and CFO of the Company is scheduled to present at the conference at approximately 8:00 a.m. CT. ZELTIQ also informed that the audio webcast of the Company's presentation and its replay will be available for 90 days at its Investor Relations website. The Full Research Report on ZELTIQ Aesthetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Clovis Oncology, Inc. Research Report
On December 2, 2013, Clovis Oncology, Inc. (Clovis) announced that certain selling stockholders have commenced an underwritten public offering of 2 million shares of the Company's common stock, which they recently acquired as consideration in connection with Clovis' acquisition of EOS (Ethical Oncology Science) S.p.A. Clovis reported that the net proceeds from the sale will be received by the selling stockholders and not by the Company, and the total number of shares of its outstanding common stock will not change as a result of the offering. Clovis also informed that the selling stockholders intend to grant J.P. Morgan Securities LLC, the sole manager for the offering, a 30-day option to purchase up to an additional 15% of the number of shares sold to cover over-allotments, if any. The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved